检索结果-南通市图书馆

Chinese expert consensus on an innovative patient‐centered approach to diagnosis and treatment of cancer

在线全文

学校读者我要写书评

暂无评论

Cancer Innovation 2024年第5期3卷 50-70页

作者： hongnan mo Ruiqi Zhong Fei Ma Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina +4 Medical Doctor Program Chinese Academy of Medical Sciences&Peking Union Medical CollegeBeijingChina

Patient‐centered care(PCC)is an innovative approach to the diagnosis and treatment of malignancy that aims to improve patients'experience during the management of their ***,despite growing interest,the concept and specifics of PCC remain *** consensus document addresses this gap by providing a literature review and a clear definition of PCC and outlines its main components as observed in real‐world *** components include daytime diagnostic and treatment procedures,in‐hospital and community‐based infusion centers,home‐based diagnostic and treatment services,smart healthcare solutions,and integration of traditional Chinese *** document delves into the implementation of PCC and explores its potential benefits.

关键词： cancer consensus management patient‐centered care quality of life

Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2019年第1期16卷 173-180页

作者： Xuelian Chen Lanying Ma Xi Wang hongnan mo Dawei Wu Bo Lan Dong Qu Hongtu Zhang Jing Huang Binghe Xu State Key Laboratory of molecular Oncology and Department of Medical Oncology National Cancer Center National Clinical Research Center for Cancer Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College-Medical Oncology Department of Gastroenterology Tumor Hospital Affiliated to Xinjiang Medical University Tumor Hospital Affiliated to Xinjiang Medical University Department of Diagnostic Radiology National Cancer Center National Clinical Research Center for Cancer Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College-Medical Oncology Department of Pathology National Cancer Center National Clinical Research Center for Cancer Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College-Medical Oncology

Objective: SHR-1210 is a new and promising anti-PD-1 agent for solid tumors. During the phase I study of SHR-1210, we encountered a novel but prevalent immune-related dermatologic toxicity: reactive capillary hemangiomas(RCHs). Thus we tried to summarize the features of RCHs and estimate their relationship with tumor ***: This prospective observational study systematically enrolled 98 patients with advanced solid tumors from April 27th,2016 to June 8th, 2017 in the context of the phase I clinical study of SHR-1210. This report focused on the skin toxicities. Patients underwent entire skin inspection every two weeks while taking medication. The clinical course of RCHs was recorded and their association with tumor response was estimated. The data cut-off date was November 15th, ***: After a median follow-up of 242(range, 29–567) days, RCHs were observed in 85.7%(84/98) of patients on cutaneous/mucosal surfaces; 84.5%(71/84) of the RCHs were evaluated as grade 1 adverse events. No grade 3 or 4 RCHs were observed. The time of onset of RCHs was dose dependent and shortest in the 400 mg-dose cohort(P mors for patients with RCHs was 28.9%(24/83). However, no responders were observed among the patients without ***: RCHs were prevalent but manageable during treatment with SHR-1210. It might add to the expanding literature regarding immune-related dermatologic adverse events.

关键词： Reactive capillary hemangiomas SHR-1210 skin toxicity anti-tumor efficacy

Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2019年第6期31卷 910-917页

作者： Bo Zhang Xi Wang Qun Li hongnan mo Xingyuan Wang Yan Song Jianping Xu Tao Qu Jing Huang Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College

Objective:Several anti-programmed cell death 1(anti-PD-1)antibodies have demonstrated potential efficacy in the treatment of advanced esophageal squamous cell cancer(ESCC).However,the response to subsequent chemotherapy after the failure of PD-1 blockade in ESCC patients has not been reported,and the optimal sequencing of immunotherapy and chemotherapy remains *** aim of the present study was to evaluate responses to irinotecan-based subsequent chemotherapy in advanced ESCC patients who had progressed after treatment with camrelizumab(SHR-1210),a novel anti-PD-1 ***:We retrospectively reviewed the medical records of patients with advanced ESCC treated with camrelizumab at a single *** patients who received subsequent irinotecan-based chemotherapy were selected for data collection and ***:Overall,a total of 28 patients were *** patients had received at least two lines of systemic treatment prior to irinotecan *** most common regimen that was administered after PD-1 blockade was irinotecan in combination with 5-fluorouracil(5-Fu)(or its derivatives),which was given to 19 *** objective response rate(ORR)and disease control rate(DCR)were 17.9%(5/28)and 64.3%(18/28),respectively,with 5(17.9%)patients achieving a partial response and 13(46.4%)having stable *** median progressionfree survival(PFS)was 3.18[95%confidence interval(95%CI),2.48-3.88]months and the median overall survival(OS)was 6.23(95%CI,4.71-7.75)*** new safety issues,either immune-related or otherwise,were ***:Our results suggested that the response to irinotecan-based chemotherapy after PD-1 blockade in advanced ESCC patients appeared similar to that previously observed in patients who had not received PD-1 antibodies,and further study in larger cohorts or randomized trials is warranted to verify our observation.

关键词： Esophageal squamous cell carcinoma irinotecan immunotherapy treatment outcomes

The molecular tumor burden index as a response evaluation criterion in breast cancer

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第8期6卷 2494-2501页

作者： Zongbi Yi Fei Ma Guohua Rong Binliang Liu Yanfang Guan Jin Li Xiaoying Sun Wenna Wang Xiuwen Guan hongnan mo Jiani Wang Haili Qian Binghe Xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Geneplus-Beijing Institute BeijingChina Department of Medical Oncology Huanxing Cancer HospitalBeijingChina State Key Laboratory of molecular Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Circulating tumor DNA(ctDNA)is a potential biomarker of prognosis and therapeutic *** conducted this study to explore the role of the molecular tumor burden index(mTBI)in ctDNA as a therapeutic response and prognostic biomarker in a larger cohort prospective phase III randomized multicenter *** collected 291 plasma samples from 125 metastatic breast cancer patients from the CAMELLIA study(NCT01917279).Target-capture deep sequencing of 1021 genes was performed to detect somatic variants in ctDNA from the plasma *** pretreatment mTBI value was correlated with tumor burden(P=0.025).Patients with high-level pretreatment mTBI had shorter overall survival than patients with low-level pretreatment mTBI,and the median overall survival was 40.9 months and 68.4 months,respectively(P=0.011).Patients with mTBI decrease to less than 0.02%at the first tumor evaluation had longer progression-free survival and overall survival(Pmography scans(88.5%and 87.5%,respectively).The patients classified as molecular responders had longer progression-free survival and overall survival than the nonmolecular responders in the overall cohort(Pmography scans were defined as representing stable disease(P=0.027 and P=0.015,respectively).The mTBI in ctDNA detected in liquid biopsies is a potential biomarker of therapeutic response and prognosis in patients with metastatic breast cancer.

关键词： breast cancer index

Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors:a retrospective study of HR+/HER2–advanced breast cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2024年第10期21卷 934-950页

作者： Qi Zhao Mingxia Jiang Jiaxuan Liu Mengqi Zhang Maiyue He Shihan Zhou Jiani Wang hongnan mo Bo Lan Peng Yuan Pin Zhang Fei Ma Qiao Li Binghe Xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

Objective:CDK4/6 inhibitors(CDK4/6is)in combination with endocrine therapy have secured a central role in the treatment of hormone receptor(HR)-positive advanced breast cancer(ABC)and have transformed the therapeutic ***-line CDK4/6i therapy in which another CDK4/6i is continued after progression on a prior CDK4/6i may still offer advantageous therapeutic ***-line CDK4/6i therapy is an area of active investigation in the ongoing pursuit to improve outcomes for patients with HR+/human epidermal growth factor receptor 2(HER2)–***:This retrospective study enrolled 82 patients with HR+/HER2–ABC who were treated with cross-line CDK4/6is(abemaciclib,palbociclib,ribociclib,and dalpiciclib)after progression with another CDK4/*** primary endpoint was progression-free survival(PFS)according to version 1.1 of the Response Evaluation Criteria in Solid *** endpoints included toxicity,objective response rate,disease control rate,and overall *** events(AEs)were graded according to version 5.0 of the Common Terminology Criteria for Adverse Events,as promulgated by the *** of Health and Human ***:Eighty-two HR+/HER2–ABC patients who received cross-line CDK4/6i therapy from January 2022 to February 2024 were *** median age of the patients was 60 *** median PFS of all patients was 7.6 months(95%CI,5.9-9.2).Cox regression analysis identified lung metastasis and a switch to endocrine therapy following prior CDK4/6i therapy as independent predictive factors for ***,patients who previously received abemaciclib and switched to palbociclib upon disease progression had a median PFS of 10.7 *** strategy of transitioning to chemotherapy after progression on a prior CDK4/6i,then to a subsequent CDK4/6i merits further *** toxicity was the most common grade≥3 *** instances of fatal safety events were ***:Cross-line CDK4/6i therapy is associated

关键词： Breast cancer prior CDK4/6 inhibitor therapy cross-line CDK4/6 inhibitor therapy PFS

Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies:real-world data in the Han population

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2022年第14期135卷 1734-1741页

作者： hongnan mo Fei Ma Qing Li Pin Zhang Peng Yuan Jiayu Wang Yang Luo Ruigang Cai Qiao Li Binghe Xu Department of Medical Oncology National Cancer CenterNational Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

Background:This study aimed to reveal the treatment patterns and clinical outcomes of diverse palbociclib-based regimens in Han patients with estrogen receptor-positive(ER+)metastatic breast cancer in routine clinical ***:The clinical data of patients with ER+metastatic breast cancer treated with palbociclib were collected from the National Cancer Center *** efficacy profile of palbociclib in this Han population was evaluated,especially for various combination *** efficacy of palbociclib-based therapy in patients with prior everolimus treatment was also ***:A total of 186 patients from 89 cities in 18 provinces in China were *** median progression-free survival(PFS)was similar among different palbociclib-combined groups(P=0.566):10.0 months(95%confidence interval[CI]3.8-16.1)in the+exemestane group,9.7 months(95%CI 6.3-13.1)in the+letrozole group,7.8 months(95%CI 5.5-10.2)in the+fulvestrant group,7.2 months(95%CI 3.2-11.3)in the+toremifene group,and 6.1 months(95%CI 1.2-11.0)in the+anastrozole ***-four patients(18.3%)had received everolimus for their metastatic disease before the prescription of *** disease control rate was significantly lower in patients who had received previous everolimus than in the everolimus-naïve group(50.0%vs.82.2%,Pmonths vs.8.8 months,P=0.001).After propensity score matching,patients pre-treated with everolimus had similar PFS(4.4 months,95%CI 0.5-8.2)compared with everolimus-naïve patients(6.1 months,95%CI 4.7-7.5,P=0.439).Conclusions:Various palbociclib-based regimens have promising efficacy in ER+metastatic breast cancer in real-world settings,even in patients who had been pre-treated with everolimus.

关键词： Metastatic breast cancer Palbociclib Progression-free survival Real-world data

Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma:Results of a prospective randomized study

在线全文

学校读者我要写书评

暂无评论

Chronic Diseases and Translational Medicine 2021年第3期7卷 190-198页

作者： hongnan mo Peng Liu Yan Qin Xiaohui He Xiaohong Han Jiarui Yao Weicai Su Shuxiang Zhang Le Tang Fengyi Zhao Lin Gui Sheng Yang Jianliang Yang Shengyu Zhou Zhishang Zhang Yuankai Shi Department of Medical Oncology Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsNational Cancer CenterNational Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100021China

Background:Chemotherapy plus granulocyte colony-stimulating factor (GCSF) regimen is one of the available approaches to mobilize peripheral blood progenitor cells (PBPCs).It causes thrombocytopenia and delays *** study aimed to evaluate the role of recombinant human thrombopoietin (rhTPO) before mobilization chemotherapy in facilitating leukapheresis in patients with ***:In this randomized open-label phase 2 trial, patients were randomly assigned in a 1:2 ratio to receive mobilization with rhTPO plus GCSF in combination with chemotherapy (the rhTPO plus GCSF arm) or GCSF alone in combination with chemotherapy (the GCSF alone arm).The recovery of neutrophils and platelets and the amount of platelet transfusion were ***:Thirty patients were enrolled in this study between March 2016 and August 2018. Patients in the rhTPO plus GCSF arm (n = 10) had similar platelet nadir after mobilization chemotherapy (P=0.878) and similar amount of platelet transfusion (median 0 vs.1 unit,P=0.735) when compared with the GCSF alone arm (n = 20). On the day of leukapheresis, the median platelet count was 86 ×10^(9)/L (range 18-219) among patients who received rhTPO and 73 ×10^(9)/L (range 42-197) among those who received GCSF alone (P=0.982). After the use of rhTPO, the incidence of platelet count more rapid in the rhTPO plus GCSF arm (median 8.0 days [95% confidence interval 2.9-13.1] to platelets ≥50 ×10^(9)/L vs. 11.0 days [95% confidence interval 8.6-13.4],P=0.011).The estimated total cost of the mobilization and reconstitution phases per patient was similar between the two treatmtent groups (P=0.362 andP=0.067,respectively).Conclusions:Our findings indicate that there was no significant clinical benefit of rhTPO use in facilitating mobilization of progenitor cells,but it may promote platelet recover

关键词： Recombinant human thrombopoietin mobilization Lymphoma Schedule

新型冠状病毒肺炎疫情期间乳腺癌患者的院外管理

在线全文

学校读者我要写书评

暂无评论

中华肿瘤杂志 2020年第4期42卷 288-291页

作者：刘斌亮马飞王佳妮樊英莫红楠徐兵河国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院内科 100021

新型冠状病毒肺炎(COVID-19)疫情蔓延迅速。为了避免人群聚集性传播,政府加强了人员流动性的管控,给乳腺癌患者的检查、治疗带来影响。在当前疫情形势下,文章结合乳腺癌患者特点及公共卫生安全因素就乳腺癌患者如何实现科学的院外管理... 详细信息

新型冠状病毒肺炎(COVID-19)疫情蔓延迅速。为了避免人群聚集性传播,政府加强了人员流动性的管控,给乳腺癌患者的检查、治疗带来影响。在当前疫情形势下,文章结合乳腺癌患者特点及公共卫生安全因素就乳腺癌患者如何实现科学的院外管理进行探讨。肿瘤患者较正常人感染COVID-19的风险更高、症状更重、恶化更快。在正确认识COVID-19危险性的基础上,更需加强自身防护。患者应结合目前所处地区的防疫情况、乳腺癌疾病阶段、前期治疗方案等因素,权衡利弊后决定下一步的治疗方案。在疫情严重区域,适当推迟就诊时间,必要时经医师与患者线上或线下的专业讨论和沟通后,寻找替代的治疗方案并注意心理健康的疏导。

关键词：新型冠状病毒肺炎乳腺肿瘤院外管理

程序性死亡蛋白1抗体SHR-1210治疗晚期实体瘤患者中肾上腺皮质功能减退的临床报道

在线全文

学校读者我要写书评

暂无评论

中华肿瘤杂志 2019年第6期41卷 466-470页

作者：汤佳琳黄镜王玺陈雪莲李群莫红楠吴大维兰波徐兵河国家癌症中心国家肿瘤临床医学研究中心中国医学科学院北京协和医学院肿瘤医院肿瘤内科100021

目的观察程序性死亡蛋白1(PD-1)抗体SHR-1210治疗晚期实体瘤患者过程中肾上腺皮质功能的变化情况.方法收集中国医学科学院肿瘤医院2016年4月27日至2017年6月8日入组PD-1抗体SHR-1210治疗的晚期实体瘤Ⅰ期临床研究的98例患者资料,分析96... 详细信息

目的观察程序性死亡蛋白1(PD-1)抗体SHR-1210治疗晚期实体瘤患者过程中肾上腺皮质功能的变化情况.方法收集中国医学科学院肿瘤医院2016年4月27日至2017年6月8日入组PD-1抗体SHR-1210治疗的晚期实体瘤Ⅰ期临床研究的98例患者资料,分析96例患者的促肾上腺皮质激素(ACTH)和血清皮质醇变化.根据临床表现、实验室检查和影像学资料诊断免疫治疗相关肾上腺皮质功能减退.结果截至2018年12月14日,96例患者中,无SHR-1210治疗相关原发性肾上腺皮质功能减退,出现免疫治疗相关的继发性肾上腺皮质功能减退的发生率为1.0%(1/96),为2级继发性肾上腺皮质功能减退.在96例患者中,无3~4级肾上腺功能减退不良反应. 1例出现肾上腺皮质功能减退患者的主要临床表现为2级乏力、2级厌食、2级头痛.自首次用药第267天后患者出现乏力和厌食,第279天后出现2级血皮质醇减低,第291天后出现头痛,结合血皮质醇持续低值,自首次用药第435天后停止SHR-1210输注,第457天后给予患者生理剂量的激素替代治疗,患者厌食等症状缓解.自首次用药第786天后患者血皮质醇仍低于正常下限,继续激素替代治疗.结论 SHR-1210治疗晚期实体瘤患者时肾上腺皮质功能减退的发生率低,激素替代治疗可有效缓解症状.临床医师应警惕此类免疫治疗相关肾上腺皮质功能减退的不良反应,避免肾上腺危象.

关键词：实体肿瘤 SHR-1210 程序性死亡蛋白1抗体继发性肾上腺皮质功能减退垂体炎